Jade Biosciences, Inc.

NASDAQ:JBIO

Biotechnology

Healthcare
$15.49 -1.25%

-$0.21 today

Market cap
$1.07B
Beta
1.45
P/E (TTM)
-7.4
EPS (TTM)
-$2.24
52W Low $6.67High $28.00

Volume 0.79M

Average 0.83M

JBIO Common Stock Issued

Cash raised by issuing new shares.

Jade Biosciences, Inc.NASDAQ: JBIO

Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026

Common stock issued of $45K in Q1 FY2026

Q1 FY2026 common stock issued was $45K. Trailing-twelve-month common stock issued was $360.66M. Over 3 fiscal years it compounded at +869.3% a year.

Context

  • Common stock issued increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock issued holds near $45K or moves back toward the trailing-twelve-month quarterly average of $90.16M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$45K-100.0% QoQ
Last fiscal yearDec 2025
$360.61M+1318.2% YoY
LTMMar 2026
$360.66M— YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+1318.2%——
3-year CAGR+869.3%——
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
360.61M USD
Year-over-year change
+1318.2%
4-year CAGR
+17.3%

Common Stock Issued vs competitors

How JBIO compares with its peers on the latest reported figures

  • JBIO's LTM Mar 2026 common stock issued of $360.66M is the largest of the 9 companies compared; the peer median is $68.3M.
  • Over three fiscal years its annual growth of +869.3% compares with a peer median of +52.8%.
JBIO Competitors Peer median
Common Stock Issued for JBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JBIOJade Biosciences, Inc.LTM Mar 2026$360.66M —+869.3%—
VERAVera Therapeutics, Inc.LTM Jun 2026$311.34M -10.5%+52.8%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$117.67M +56670.7%——
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$112.69M +3.5%——
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$78.57M +31216.6%+2580.0%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$58.03M -22.6%—693.6%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$53.58M -59.8%——
DWTXDogwood Therapeutics, Inc.LTM Mar 2026$11.26M -46.6%-1.1%—
TRAXFirst Tracks Biotherapeutics IncFY2025$0 -100.0%——
Peer median (excluding JBIO) $68.3M-16.5%+52.8%693.6%

Competitors are the stored peer set for JBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(22.96M)(51.51M)(75.52M)(69.63M)(127.41M)
Depreciation & Amortization15K68K96K282K26K
Deferred Income Tax00000
Stock-Based Compensation00000
Change in Working Capital(6.51M)7.76M9.8M(11.17M)(8.2M)
Accounts Receivables00000
Inventory00000
Accounts Payables609K1.37M(164K)(2.17M)361K
Other Working Capital(7.12M)6.39M9.96M(9M)(8.56M)
Other Non-Cash Items2.06M4.57M8.85M9.32M40.89M
Operating Cash Flow(27.4M)(39.12M)(56.78M)(71.2M)(94.69M)
Capital Expenditures(181K)(195K)(142K)0(196K)
Acquisitions (Net)00000
Purchases of Investments(113.25M)(147.62M)(123.98M)(19.68M)(261.19M)
Sales of Investments0154.74M136M75.71M14.42M
Other Investing Activities0000(31K)
Investing Cash Flow(113.43M)6.93M11.88M56.03M(247.01M)
Debt Repayment00000
Common Stock Issued190.46M396K46M25.43M360.61M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0000156K
Financing Cash Flow190.46M396K46M25.43M360.77M
Effect of Forex Changes0000(52.82M)
Net Change in Cash49.62M(31.8M)1.09M10.26M54.69M
Free Cash Flow(27.58M)(39.32M)(56.92M)(71.2M)(94.89M)

Jade Biosciences, Inc.

NASDAQ:JBIO

Intrinsic Alpha fair value

Locked

Current Price

$15.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.